Zalcitabine

Drug Profile

Zalcitabine

Alternative Names: D 2C; ddC; Dideoxycytidine; Hivid; NSC 606170; RO 24-2027/000

Latest Information Update: 17 Apr 2015

Price : $50

At a glance

  • Originator Roche
  • Class Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Market Withdrawal HIV infections

Most Recent Events

  • 09 Jul 1999 Coronavirus-DNA-vaccine-NIAID Coronavirus-DNA-vaccine-VRC/NIAID
  • 22 Jan 1999 Launched for HIV infections treatment in Australia (PO)
  • 02 Jun 1998 Launched for HIV infections treatment in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top